Compare Dow Inc (DOW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Twist Bioscience Corp — how do they compare? Dow Inc trades at $28.35 (market cap $20.06B), while Twist Bioscience Corp trades at $157 (market cap $10.08B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays a 5.04% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Twist Bioscience Corp for 27 Days on average.
| DOW | TWST | |
|---|---|---|
Market Cap | $20.06B | $10.08B |
Volume | 7,817,231 | 4,229,037 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $205.00 |
52-Week Low | $20.65 | $25.45 |
Typical Hold Time | 82 Days | 27 Days |
Enterprise Value | $35.75B | $10.01B |
Dividend Yield | 5.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company shows mixed fundamentals with negative net income margin of -3.13% and ROE of -7.86%, though recent earnings have beaten expectations. Cash flow trends show operational improvement from $1.03B in 2025 to projected $3.9B in 2026. Analyst consensus is mixed with 27.8% buy ratings and a $34.22 price target, representing 23% upside potential.
While DOW faces margin pressures and declining revenue, the stock trades at attractive valuation multiples with P/S of 0.48. The dividend remains intact with $0.35 payment scheduled for September 2026. Key risks include ongoing profitability challenges and chemical sector headwinds, but earnings beats and cash flow improvement provide potential catalysts for patient investors.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
